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Structure-guided development of heterodimer-
selective GPCR ligands
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Crystal structures of G protein-coupled receptor (GPCR) ligand complexes allow a rational
design of novel molecular probes and drugs. Here we report the structure-guided design,
chemical synthesis and biological investigations of bivalent ligands for dopamine D2 receptor/
neurotensin NTS1 receptor (D2R/NTS1R) heterodimers. The compounds of types 1–3 consist
of three different D2R pharmacophores bound to an afﬁnity-generating lipophilic appendage,
a polyethylene glycol-based linker and the NTS1R agonist NT(8-13). The bivalent ligands show
binding afﬁnity in the picomolar range for cells coexpressing both GPCRs and unprecedented
selectivity (up to three orders of magnitude), compared with cells that only express D2Rs. A
functional switch is observed for the bivalent ligands 3b,c inhibiting cAMP formation in cells
singly expressing D2Rs but stimulating cAMP accumulation in D2R/NTS1R-coexpressing cells.
Moreover, the newly synthesized bivalent ligands show a strong, predominantly NTS1R-
mediated b-arrestin-2 recruitment at the D2R/NTS1R-coexpressing cells.
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G
protein-coupled receptors (GPCRs) form the largest
family of membrane proteins1. Because of their diversity
and critical involvement in numerous cellular signalling
processes in both central nervous system (CNS) and periphery,
GPCRs represent today’s most popular drug targets attracting
interdisciplinary scientiﬁc attention. Consequently, large progress
has been made in understanding GPCR structures and modes of
function. A growing number of studies showed that GPCRs not
only exist as isolated entities but also interact within the plasma
membrane by forming receptor dimers or higher-order
oligomers2–5. Besides enabling cross-talk between individual
signalling networks, receptor dimerization can induce activation
of alternative signalling pathways6,7, inﬂuence ligand
pharmacology and is critical for receptor trafﬁcking and
function3.
Dopamine D2 receptors (D2Rs), which belong to the family A
of GPCRs, regulate a large number of physiological functions and
are involved in a number of neuropsychiatric disorders including
schizophrenia and Parkinson’s disease. Along with numerous
other GPCRs, D2Rs have been proven to form homodimers8,9
and heterodimers10–14, and growing evidence indicates that
altered D2R cooperativity may signiﬁcantly contribute to CNS
disorders15,16. Among receptors interacting with D2Rs in the
CNS, the neurotensin receptor subtype 1 (NTS1R) together with
its endogenous ligand, the tridecapeptide neurotensin, has gained
substantial interest over the past decades. Both GPCRs are closely
associated and highly co-localized in vivo17. For example, more
than 80% of dopaminergic neurons in the mesolimbic system
express NTS1R (ref. 18). Moreover, neurotensin was found to
decrease the D2R-afﬁnity for dopamine and other agonists in
striatal19 and co-transfected HEK 293 T membrane
preparations20. Evidence for the physical intramembrane
interaction of both receptors was also conferred by means of
bioluminescence resonance energy transfer, co-
immunoprecipitation and attenuation of dopaminergic
signalling in co-transfected human cells20,21. Since central
administration of the neuropeptide in animals can mimic the
effects of neuroleptic treatment, neurotensin has been
hypothesized to act as endogenous antipsychotic22.
Powerful tools for studying GPCR dimerization are bivalent
ligands consisting of two pharmacophores tethered by an
appropriate linker23,24. Bivalent ligands bridging the proximate
orthosteric-binding sites of a dimer provide valuable insights into
the quaternary structure of receptor dimers and the functional
relevance of GPCR dimerization. Because of their selective
recognition properties, bivalent ligands can be used for a tissue-
speciﬁc targeting of cells expressing an individual GPCR dimer.
Pioneering work in this ﬁeld was performed developing dimer-
preferring ligands to investigate opioid receptor dimerization
in vitro and in vivo25–27 and further compounds were synthesized
to target GPCR homo- and heterodimers28–33. In theory, bivalent
ligands successfully bridging two binding sites of adjacent
protomers should confer extremely high afﬁnity (resulting from
the total binding energy of two recognition elements) and thus
selectivity for the heterodimer. Most of the previous reports have
shown compounds with only modest preference for heterodimers
over monomers.
High-resolution crystal structures of GPCR-ligand complexes
open new opportunities for the design of bivalent ligands. A
carefully designed bivalent ligand bridging two neighboured
receptor protomers should exhibit extremely high binding
afﬁnity. This approach should lead to high tissue selectivity
between heterodimer-expressing cells and those that express only
one individual receptor6. Our work presents heterobivalent D2R/
NTS1R ligands of type 1-3 comprising NT(8-13), the active
fragment of the neuropeptide neurotensin, covalently linked to
three different D2R-speciﬁc pharmacophores. These newly
synthesized bivalent compounds exhibit high selectivity up to
three orders of magnitude and picomolar Ki values in
D2R/NTS1R-coexpressing cells compared with cells expressing
D2R only. Using bivalent ligands containing an agonist D2R
pharmacophore substructure, we demonstrate that Gi/Go-
promoted D2R signalling is attenuated in the D2R/NTS1R
coexpressing cells, while the compounds behave as full
dopamine receptor agonists in cells singly expressing D2R.
Results
Design. To design heterobivalent ligands, we intended to connect
three different D2R pharmacophores to the NTS1R agonist NT(8-13)
via an afﬁnity-generating biphenyltriazole-moiety (lipophilic
appendage)34,35 and o-amino acid-functionalized polyethylene
glycol (PEG) spacers (Fig. 1). As D2R pharmacophores, we used
the D2R/D3R antagonist eticlopride, co-crystallized in complex
with D3R (ref. 36), the privileged structure of a phenylpiperazine-
based scaffold37 and an aminoindane-type agonist32. Suitable
attachment points for the connection of the pharmacophores
with the linker were identiﬁed using the crystal structures of
NTS1R (refs 38,39) and D3R (ref. 36). Inspection of the crystal
structures revealed that the N-terminus of NT(8-13) and the 4’-
position of eticlopride are accessible from the extracellular side. In
an effort to determine a suitable linker length, we generated a
D2R/NTS1R heterodimer model (Fig. 2) consisting of a D2R
homology model40 (which was based on the D3R crystal
structure) and the NTS1R crystal structure39 (Supplementary
Note 1; Supplementary Tables 1,2; and Supplementary Fig. 1). As
templates to build the dimer model, we considered 16 crystal
structures of 12 different GPCRs displaying homodimers with 18
individual receptor orientations. We generated dimer models
based on every template. Models were not considered further if
they showed substantial clashes between the two receptors, as well
as models revealing a high distance between the protomers or
showing a low parallelism of the two protomers. Showing
relatively high sequence similarity with D2R, the structure of a
b1-adrenergic receptor (b1-AR) homodimer41 was selected as a
template for the generation of the heterodimer model. The crystal
structure revealed a dimer interface involving transmembrane
helix 1 (TM1), TM2 and helix 8 (H8) that was previously
reported to be important for D2R dimerization8 and validated by
crosslinking studies at b1-AR (ref. 41). The model showed a
minimum distance (beeline) of 42Å between the attachment
points of eticlopride and NT(8-13) (Fig. 2 and Supplementary
Note 2). However, docking of eticlopride with the afﬁnity-
generating biphenyltriazole-moiety into the heterodimer model
revealed two reasons why a longer spacer length should be
required. First, the binding pocket of D2R restricts the D2R-
attachment in a position not facing straight towards NTS1R
(Supplementary Fig. 2a) and in addition, the way is partially
blocked by the extracellular loop 1 of D2R and the N-terminus of
NTS1R, resulting in a total distance ofB55Å. We concluded that
at least two PEG-units, in addition to the biphenyltriazole-based
attachment, should be necessary to enable a bivalent-binding
mode (ligand 1b), while a ligand containing only one PEG-unit
(ligand 1a, corresponding to a maximal linker length of B46Å)
should lack the ability to bridge the two binding sites and could
thus serve as a control agent (Supplementary Fig. 2b). To
determine an optimum linker length, we additionally designed
compounds 1c and 1d bearing three and four units of the
functionalized PEG-spacer, respectively. Using an identical
approach, we designed the bivalent compounds of types 2 and
3 featuring phenylpiperazine- and aminoindane-based D2R
pharmacophores. Here, the attachment points at the
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pharmacophores were identiﬁed based on docking studies
(Supplementary Note 2 and Supplementary Fig. 3). We
performed molecular dynamics (MD) on the bivalent ligands
1b, 2b and 3b (400 ns for each compound) in complex with the
generated heterodimer model, because ﬂaws in the process of
ligand design would potentially appear as instabilities in the
simulation systems. All three systems adopted stable receptor–
ligand complexes during this time (Supplementary Note 3;
Supplementary Fig. 4; and Supplementary Data 1–3).
Synthesis. Chemical synthesis was conducted on solid phase
involving the generation of the peptidic sequence, followed by
ligation of the individual linker and coupling with the carbox-
ylate-functionalized dopaminergic pharmacophore. The afﬁnity-
generating biphenyltriazole-moieties were installed using click
chemistry. To generate appropriate control agents, we linked the
dopaminergic building blocks to a peptide–peptoid hybrid of
NT(8-13) (ref. 42), which is highly similar to NT(8-13) but shows
only poor NTS1R afﬁnity (compounds 2e,f, 3e,f; Fig. 1 and
Supplementary Table 3).
Radio-ligand binding. Binding proﬁles of the bivalent ligands of
types 1–3 were determined by displacement of the radio-ligand
[3H]spiperone from the human D2R in membranes from HEK
293T cells singly expressing the D2R and in D2R/NTS1R-coex-
pressing cells (Table 1). Test compounds 1a, 2a and 3a containing
biphenyltriazole-substituted eticlopride, phenylpiperazine and
aminoindane moieties, respectively, linked to NT(8-13) by a short
22-atom spacer to NT(8-13) showed acceptable binding afﬁnities
to the D2R with Ki values ranging from 1.4 and 1.7 nM for 1a up
to double-digit nanomolar values for 2a and 3a, in D2R and D2R/
NTS1R expressing membranes (Table 1 and Fig. 3a–c). Extension
of the linker to 44 atoms resulted in comparable afﬁnities for 1b,
2b and 3b at the D2R monoexpressing cells, (Ki 9.9, 42 and
36 nM). However, binding characteristics at the D2R/NTS1R-
coexpressing cells were changed dramatically by the elongation of
the linker. Thus, we observed biphasic competition curves with
two individual values for Ki high and Ki low (Fig. 3d–f). For all
three compounds, high-afﬁnity binding was observed at
subnanomolar concentrations (Ki high 0.11–0.47 nM) with a high-
afﬁnity population of 31–55%, while the afﬁnity for the low-
afﬁnity site ranged from 43 to 630 nM (Table 1). We suggest that
the high-afﬁnity Ki values represent a bivalent receptor-bridging
binding mode of 1b, 2b and 3b to D2R/NTS1R heterodimers,
whereas low-afﬁnity Ki values reﬂect a monovalent-binding mode
to D2R as a monomer or within a homo-/heterodimer. Thus,
these newly designed ligands exhibit a 76–200-fold preference for
the high-afﬁnity bivalent interaction with the D2R/NTS1R het-
erodimer over monovalent-binding modes to D2R monoexpres-
sing membranes.
In contrast, the respective analogues 2e/f and 3e/f (spacer
length 22 and 44 atoms), containing a peptide–peptoid hybrid
with almost no afﬁnity for NTS1R instead of the highly similar
peptide NT(8-13), displayed monophasic-binding curves at both,
D2R and D2R/NTS1R-coexpressing membranes (Ki 15-40 nM
for D2R and Ki 22–110 nM for D2R/NTS1R; Supplementary
Fig. 5a–d). Typical monophasic-binding curves were also
observed for the monovalent analogues of types 2 and 3 ligands
2g and 3g for both expression systems (Ki 20 and 21 nM for 2g
and 3g at D2R and Ki 42 and 42 nM for 2g and 3g at D2R/NTS1R,
respectively; Supplementary Fig. 5e,f).
In an attempt to ﬁnd an optimum linker length, we also
investigated the binding behaviour of compounds 1c–3c and 1d–3d
with a spacer length of 66 and 88 atoms, respectively. Whereas
ligands 1c and 1d maintained one-digit nanomolar afﬁnity (Ki 2.5
and 9.0 nM), elongation of the spacer led to a loss of binding
afﬁnity for types 2 and 3 ligands (Ki 140–520 nM) at D2R
monoexpressing membranes. Nevertheless, the biphasic-binding
proﬁles with separated high- and low-afﬁnity sites at D2R/
NTS1R-coexpressing membranes were preserved or even
enhanced for ligands 1c–3c and 1d–3d (Ki high 0.087–2.6 nM,
Ki low 120–1,800 nM, Fig. 3g–l). Within the entire set of
compounds, ligand 2d (spacer length 88 atoms) displayed the
outstanding afﬁnity of 87 pM for the high-afﬁnity binding site.
Interestingly, the preference for the high-afﬁnity binding site
versus the afﬁnity for D2R monoexpressing membranes was more
pronounced for types 2 and 3 ligands based on phenylpiperazines
or aminoindane as D2R pharmacophores (76–4,700-fold),
compared with the eticlopride-based derivatives (3.5–90-fold),
D2R pharmacophore Lipophilic appendage Spacer NTS1R pharmacophore
1a: m = 1
1b: m = 2
1c: m = 3
1d: m = 4
2a: m = 1, X = Tyr
2b: m = 2, X = Tyr
2c: m = 3, X = Tyr
2d: m = 4, X = Tyr
2e: m = 1, X = NhTyr
2f: m = 2, X = NhTyr
3a: m = 1, X = Tyr
3b: m = 2, X = Tyr
3c: m = 3, X = Tyr
3d: m = 4, X = Tyr
3e: m = 1, X = NhTyr
3f: m = 2, X = NhTyr
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Figure 1 | Newly synthesized bivalent ligands. Type 1-3 ligands contain NT(8-13) as NTS1R pharmacophore and differ in their D2R recognition element
(type 1: eticlopride, antagonist; type 2: 2-methoxyphenylpiperazine, antagonist; and type 3: aminoindane, agonist). The spacer length connecting both
pharmacophores ranges from 22 to 88 atoms (m¼ 1–4). For bivalent control compounds 2e/f and 3e/f, tyrosine was replaced by N-homotyrosine (NhTyr).
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with comparable fractions of high-afﬁnity binding sites (50–66%
high-afﬁnity fraction).
Additional binding assays were performed in the presence of an
excess of NT(8-13) (1mM), which should prevent a bivalent-binding
mode of the test compounds to D2R/NTS1R-coexpressing mem-
branes by displacing the NT(8-13) pharmacophore of the bivalent
ligands from NTS1R. In fact, co-incubation prevented high-afﬁnity
binding, resulting in typical sigmoidal monophasic curves (Fig. 4a
and Supplementary Fig. 6a). Detailed analyses revealed a slightly
reduced D2R-afﬁnity in the presence of the monovalent NTS1R
agonist, which is in agreement with the reduced Ki low observed for
bivalent ligands at D2R/NTS1R-coexpressing membranes compared
with D2R monoexpression (Table 1). Importantly, these ﬁndings are
consistent with earlier studies demonstrating a negative effect of
neurotensin especially on D2R agonist afﬁnity19,20. The binding
properties of the reference antagonist spiperone remained almost
constant under these conditions (Ki 0.073 and 0.080nM, n¼ 3, in
the absence and presence of 1mM NT(8-13), respectively).
However, even in the absence of NT(8-13), slight differences
between the afﬁnity for D2R monoexpressing membranes and the
low-afﬁnity binding site of D2R/NTS1R-coexpressing membranes
were observed, suggesting that more complex ligand/receptor
interactions might take place in the coexpressing membranes.
Moreover, the simultaneous presence of at least three binding
modes (bivalent and monovalent to D2R/NTS1R heterodimer,
monovalent to D2R monomer) should putatively result in
triphasic-binding curves, which we have not been able to resolve.
Above described experiments were performed with a twofold
excess of NTS1R, concluding that most of [3H]spiperone-bound
D2R were able to form D2R/NTS1R heterodimers. By changing
the ratio towards a two- or three-fold excess of D2R, the high-
afﬁnity fraction, which corresponds to the bound receptor
heterodimer, was rightward shifted and the biphasic character
of the curve was gradually diminished (Supplementary Fig. 6b).
Thus, a correlation between the ratio of protomers and the
formation of molecular entities bound by bivalent ligands with
particularly high afﬁnity could be demonstrated.
Further competition experiments with the bivalent ligands 2b
and 3b were conducted in presence of the non-hydrolysable GTP
analogue GppNHp, thereby destabilizing receptor-G protein
association. In fact, co-incubation with 100 mM GppNHp had
no inﬂuence on the binding behaviour of the bivalent ligand 2b at
membranes from D2R-expressing cells (Ki – GppNHp 42±5 nM
versus KiþGppNHp 45±6 nM). In contrast, a slight rightward shift
of the Ki was observed for compound 3b, which is in good
agreement with its D2R agonist pharmacophore (Ki – GppNHp
36±9 nM versus KiþGppNHp 68±8 nM). However, at
D2R/NTS1R-coexpressing membranes, a rightward shift of the
high-afﬁnity binding site occurred for both compounds (5.2- and
6.4-fold for 2b and 3b, respectively, Supplementary Fig. 7a,b).
These changes are expected, since the agonist NT(8-13) as
NTS1R-recognizing fragment is part of both bivalent ligands, and
agonist afﬁnity is strongly dependent on the presence of G
proteins. Nonetheless, in the presence of GppNHp, the biphasic-
binding behaviour is retained, leading to a 330- and 190-fold
preference for the high- over the low-afﬁnity binding site in D2R/
NTS1R-coexpressing membranes.
To conﬁrm the bivalent receptor-bridging binding mode, we
performed reciprocal competition experiments by labelling the
NTS1R with the radio-ligand [3H]neurotensin. Therefore, we
used a homogenate with a 2.5-fold excess of D2R. Employing 3b,
we observed a biphasic-binding curve in cells expressing the D2R/
NTS1R heterodimer with a Ki high value of 0.11 pM and a Ki low at
1.7 nM, which was shifted to a monophasic sigmoidal binding
curve in the presence of haloperidol (Ki 0.79 nM, Fig. 4b). Hence,
incubation with the monovalent D2R antagonist efﬁciently
prevented the bivalent-binding mode. Afﬁnities for this competi-
tion-enforced monovalent-binding mode were found to be in
good agreement with results obtained with membranes from
CHO-cells stably expressing NTS1R only (Ki 0.86 nM;
Supplementary Table 3 and Supplementary Methods).
To complement the results obtained with overexpressing
heterologous cell lines with results from native brain tissue,
competition-binding studies with [3H]spiperone and the bivalent
ligand 3b in comparison with the control agent 3f (both with a
spacer length of 44 atoms) were performed with membranes from
porcine striatum. Convincingly, test compound 3b displayed a
biphasic-binding behaviour with a 140-fold preference for the
high-afﬁnity binding site over the low-afﬁnity receptor population
(Ki high 2.8 nM, Ki low 310 nM, high-afﬁnity fraction 38%). In good
agreement with the results from heterologous cell lines, addition of
1mM NT(8-13) reverted this biphasic-binding curve to a sigmoidal
binding isotherm with a Ki value of 28nM. In contrast, typical
monophasic-binding curves with Ki values of 28 and 29nM were
OH O
O
O
O
OH
Cl
N
N
H
H2N
H2N
HN
NH
Eticlopride NT(8–13)
42 Å
D2R NTS1R
Arg–Pro–Tyr–IIe–Leu
Figure 2 | A structure-guided approach for the design of bivalent ligands.
On the basis of X-ray crystal structures, a D2R/NTS1R heterodimer model
was generated and exploited for the design of bivalent ligands. A side view
of dimer model is displayed at the bottom half and the ligand structures at
the top of the ﬁgure. The middle part shows a magniﬁed top view of the
dimer model. Ribbons and surfaces of D2R and NTS1R are coloured in grey
and red, respectively. Eticlopride (green) and NT(8-13) (blue) were
positioned according to their coordinates in the crystal structures of D3R
and NTS1R, respectively. Clearly, the N-terminus of NT(8-13) and the 4’-
position of eticlopride are accessible from the extracellular side and were
therefore selected as attachment points (highlighted as pink spots in all
three representations). The beeline and hence the minimum distance
connecting these two attachment points measures 42Å.
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observed in the absence and presence of 1mM NT(8-13) for the
highly similar peptide–peptoid hybrid ligand 3f, which proved to
have almost no afﬁnity for NTS1R (Fig. 4c,d). Thus, the connection
of D2R- and NTS1R-addressing pharmacophores by an appropriate
linker allows the superior recognition of heterodimers over
monomers or homo(oligo-)mers not only in heterologous cell
lines but also in native tissue. However, the observed preferences
are less pronounced in striatal membranes, which might be, at least
in part, explained by lower receptor expression levels leading to a
lower propensity to form D2R/NTS1R heterodimers.
Functional evaluation. To measure activation proﬁles of the
bivalent ligands 2b and 3b and their monovalent analogues 2g
and 3g comprising the pharmacophore of a D2R antagonist and a
D2R agonist, respectively, we performed a BRET-based cAMP
accumulation assay43. Coupling to inhibitory Gai/o proteins, the
stimulation of the D2R leads to a decrease of cAMP, whereas
activation of the Gas-coupled NTS1R increases adenylyl cyclase
activity. As expected, the reference agonist quinpirole potently
inhibited forskolin-induced cAMP accumulation in cells
expressing D2R only, while the phenylpiperazine-derived
ligands 2b and 2g and the NTS1R-binding fragment NT(8-13)
remained without signiﬁcant effects (Fig. 5a).
Since we were unable to detect intrinsic activity for type 2
ligands in our cAMP accumulation assay, we tested the
representative bivalent and monovalent ligands 2b and 2g for
their capacity to prevent quinpirole-mediated inhibition of cAMP
accumulation. As expected, both ligands were able to fully inhibit
the effect of 10 nM quinpirole. In comparison, the type 1 ligand
1b and its pharmacologically active D2R fragment eticlopride
were more potent and even showed an inverse agonist effect,
leading to a 20–32% change in the basal cAMP level
(Supplementary Fig. 8). The bivalent ligand 3b and the
monovalent dopaminergic 3g bearing the aminoindane moiety
displayed functional properties that were highly similar to
quinpirole. Observed potencies (EC50) were in the low nanomolar
range (2.3–5.0 nM), and maximum efﬁcacies did not differ
signiﬁcantly among the three investigated D2R agonists (Fig. 5d
and Supplementary Table 4). In cells expressing only NTS1R,
neither the monovalent ligands 2g, 3g, nor quinpirole were able
to exhibit receptor activation. However, the bivalent ligands 2b
and 3b were as effective as NT(8-13), albeit at 10-fold higher
concentrations (EC50 2.6 nM for NT(8-13) versus EC50 20.7 and
30.6 nM for 2b and 3b, Fig. 5b,e). In D2R/NTS1R-coexpressing
cells, quinpirole and the monovalent D2R agonist 3g inhibited
cAMP formation with similar potencies compared with cells
monoexpressing D2R. The monovalent phenylpiperazine 2g had
no effect on the intracellular cAMP concentration. Interestingly,
all investigated bivalent ligands increased cytosolic cAMP in a
similar manner as NT(8-13). Observed potencies were compar-
able to the monoexpressing NTS1R cells (EC50 2.0 nM for NT(8-
13) versus 39.3 and 70.0 nM for 2b and 3b, respectively), although
a slight loss in potency could be observed for the bivalent ligands
(Fig. 5c,f). The extremely high afﬁnity of the bivalent ligands
could not be transduced into an increase in potency at D2R/
NTS1R-coexpressing cells. When the spacer connecting the D2R
and NTS1R pharmacophores was elongated to 66 atoms for the
bivalent ligands 2c and 3c, similar observations concerning the
activation of D2R, NTS1R and D2R/NTS1R heterodimers were
made (Supplementary Fig. 9a–c and Supplementary Table 4).
The absence of D2R-mediated inhibition of cAMP accumula-
tion in cells coexpressing D2R/NTS1R, is not speciﬁc for bivalent
ligands, since a comparable attenuation of dopaminergic signal-
ling is achieved when D2R/NTS1R-coexpressing cells are
stimulated with quinpirole and NT(8-13) simultaneously
(Supplementary Fig. 10a). In contrast, a reciprocal inhibition of
NTS1R signalling by increasing concentrations of D2R agonist
could not be observed (Supplementary Fig. 10b).
To exclude interference from forskolin stimulation or the
relative receptor stoichiometry, experiments were also performed
in the absence of forskolin and under conditions leading to
Table 1 | D2R-afﬁnity for ligands 1a–d, 2a–g and 3a–g determined by [
3H]spiperone displacement.
Comp. Spacer length* D2LR
w Coexpressed D2LR/NTS1R
z
Ki Ki
y Ki high
|| Fraction highz Ki low
# Ki
** [þ 1lM NT(8-13)]
1a 22 1.4±0.7 (4) 1.7±0.1 (3) — — — 88±23 (3)
1b 44 9.9±1.4 (4) — 0.11±0.09 (5) 31±6 43±21 86±27 (3)
1c 66 2.5±1.2 (4) — 0.35±0.17 (7) 66±5 120±40 12±5 (3)
1d 88 9.0±2.6 (3) — 2.6±0.9 (4) 51±5 280±40 63±32 (3)
2a 22 19±6 (10) 32±5 (11) — — — 150±60 (3)
2b 44 42±5 (11) — 0.21±0.07 (11) 55±3 630±100 85±18 (6)
2c 66 140±20 (5) — 0.19±0.10 (6) 61±2 1,500±600 340±100 (3)
2d 88 410±150 (4) — 0.087±0.021 (8) 62±3 1,800±900 720±210 (3)
2e 22 23±5 (4) 30±2 (4) — — — 96±59 (3)
2f 44 40±6 (4) 63±11 (4) — — — 200±53 (3)
2g monovalent 20±2 (3) 42±5 (6) — — — 23±6 (4)
3a 22 20±5 (12) 72±23 (11) — — — 280±70 (3)
3b 44 36±9 (12) — 0.47±0.14 (22) 50±2 300±40 63±8 (6)
3c 66 150±40 (7) — 0.43±0.20 (7) 50±4 1,000±300 880±300 (3)
3d 88 520±280 (4) — 0.21±0.16 (4) 53±6 380±220 550±150 (3)
3e 22 15±2 (4) 22±4 (4) — — — 59±14 (3)
3f 44 39±4 (4) 110±20 (4) — — — 190±60 (3)
3g monovalent 21±4 (3) 42±12 (6) — — — 97±23 (5)
*Number of atoms reﬂecting the distance between the dopamine and the NT(8-13) pharmacophore.
wKi values in nM of the competition curves determined with membranes from HEK 293 T cells transiently transfected with D2LR.zKi values in nM derived from monophasic or biphasic ﬁtting of experiments with membranes from HEK 293T cells expressing D2LR and NTS1R.
yKi values in nM of monophasic competition curves.
||Ki values in nM for the high-afﬁnity binding site of biphasic competition curves.
zFraction representing the high-afﬁnity binding site in %.
#Ki values in nM for the low-afﬁnity binding site of the biphasic competition curves.
**Ki in nM resulting from monophasic ﬁtting of experiments in the presence of 1mM NT(8-13).
Values are given as mean±s.e.m resulting from (n) individual experiments each performed in triplicate.
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enhanced NTS1R expression and therefore higher propensity to
obtain D2R/NTS1R heterodimers. As illustrated in Supplementary
Fig. 11a–e, these modiﬁcations did not result in signiﬁcant
changes of the receptor activation proﬁles of quinpirole,
NT(8-13) or the bivalent ligands 2b and 3b. Coexpression of
NTS1R and a signalling incompetent D2R-mutant (D80A)44,45
led to a loss of dopamine receptor signalling for the monovalent
dopaminergic 3g and quinpirole while preserving the
above described biphasic-binding behaviour and the activation
proﬁle of bivalent ligand 3b (Supplementary Fig. 12a,b) in
D2R_D80A/NTS1R-coexpressing cells.
Besides G proteins, a class of adaptor proteins called
b-arrestins are frequently found to interact with GPCRs. The
recruitment of b-arrestin to a GPCR can lead to internalization
but also initiate signalling events distinct from the G protein-
mediated response46. To investigate the interaction of D2R/
NTS1R heterodimers with b-arrestin-2, we made use of an assay
system based on enzyme complementation (DiscoveRx
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Figure 3 | Biphasic competition-binding curves indicate a bivalent binding mode. Dopamine receptor binding of the bivalent ligands 1a–d, 2a–d and 3a–d
was measured by displacement of the radio-ligand [3H]spiperone from membranes of HEK 293T cells coexpressing D2R/NTS1R (blue open circles) or
monoexpressing D2R only (grey ﬁlled circles). (a-c) Bivalent ligands with a spacer length of 22 atoms (m¼ 1) result in monophasic competition-binding
curves. (d–l) Biphasic-binding curves indicating bivalent ligand binding are observed when the linker length is increased to 44, 66 or 88 atoms (m¼ 2–4) at
membranes coexpressing both target receptors (D2R/NTS1R) but not at membranes with D2R only. Data points represent the mean±s.e.m. of 3–22
independent experiments (see Table 1 for details), each performed in triplicate.
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PathHunter). Hence, HEK 293 cells stably expressing b-arrestin-2
fused to an enzyme acceptor (EA, galactosidase fragment) were
transiently transfected with ProLink-tagged D2R together with or
without cotransfection of wild-type NTS1R. Upon recruitment of
b-arrestin-2 to D2R, the following enzyme complementation leads
to conversion of a substrate and thereby chemiluminescence. The
D2R agonist quinpirole induced b-arrestin-2 recruitment in D2R
monoexpressing and D2R/NTS1R-coexpressing cells with similar
potencies (EC50 55±3 versus 75±11 nM). Interestingly,
stimulation with NT(8-13) induced b-arrestin-2 recruitment in
the coexpressing cells, but not cells singly expressing D2R,
indicating that b-arrestin-2 recruitment by NTS1R can be
detected if it occurs in close proximity of D2Rs, as for example
within a D2R/NTS1R heterodimer. Although the maximum effect
remained below the response of quinpirole (77±3%), NT(8-13)
elicited that response at 10-fold lower concentrations (EC50
7.5±2.1 nM; Fig. 6a,b). Application of an equimolar combination
of both agonists led to an even enhanced efﬁciency of b-arrestin-2
recruitment (Emax 136±6%; Supplementary Fig. 13a).
For the bivalent ligands of the phenylpiperazine-type 2a and 2b
with 22- and 44-atom spacers, no b-arrestin-2 recruitment was
observed in cells expressing D2R only, which is in good agreement
with the antagonist properties observed for 2a and 2b in the
cAMP accumulation assay. Interestingly, a bell-shaped dose–
response curve was observed for the bivalent ligand 2b in D2R/
NTS1R-coexpressing cells. Maximum b-arrestin-2 recruitment
was determined at a concentration of 300 nM (Emax 133%), while
higher ligand concentrations led to an attenuated response
(Fig. 6c). In contrast, a typical sigmoid dose–response curve was
observed for the analogue 2a with the shorter 22-atom spacer
(EC50 110±20 nM, Emax 88±4%, Fig. 6d). As expected, the
bivalent ligands 3a and 3b bearing the aminoindane-type D2R
agonist substructure elicited b-arrestin-2 recruitment in cells
monoexpressing D2R (EC50 1,500±500 nM, Emax 87±5% and
EC50 580±130 nM, Emax 82±1% for 3a and 3b respectively,
Fig. 6e,f). Highly similar to the activation proﬁles of type 2
compounds, a bell-shaped dose–response curve with a maximum
effect at a concentration of 300 nM to 1 mM (Emax 136%) was
observed when NTS1R was coexpressed for 3b (44-atom spacer),
but not 3a (22-atom spacer, EC50 37±8 nM, Emax 105±9%,
Fig. 6e,f). Bell-shaped dose–response curves with enhanced
efﬁcacy were also observed for the bivalent ligands 2c and 3c
(66-atom spacer; Supplementary Fig. 13b,c).
Additional experiments were performed employing a Pro-
Link-tagged signalling incompetent D2R_D80A mutant coex-
pressed with NTS1R. Under these conditions, only NTS1R-
mediated b-arrestin-2 recruitment can be detected. As expected,
the NTS1R agonist NT(8-13), but not the D2R agonist
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Figure 4 | Prevention of bivalent binding mode abolishes biphasic competition curves. (a) Dopamine receptor binding of 3b (m¼ 2, 44-atom spacer) at
D2R/NTS1R in the absence (blue open circles) or presence (blue inverted triangles) of 1 mM NT(8-13). Incubation with the monovalent NTS1R agonist
NT(8-13) prevents a bivalent binding mode and converts the biphasic-binding curve (Ki high 0.47±0.14 nM, Ki low 300±40nM, n¼ 22) into a monophasic
sigmoid competition curve (Ki 63±8 nM, n¼6). (b) Neurotensin receptor binding of 3b (m¼ 2) at D2R/NTS1R in the absence (blue open circles) or
presence (blue ﬁlled triangles) of 1 mM haloperidol. Incubation with the monovalent D2R antagonist prevents the bivalent binding mode, observed for the
coexpression of D2R/NTS1R (Ki high 0.11±0.05 pM, Ki low 3.7±1.4 nM, n¼ 9 versus Ki 0.79±0.21 nM, n¼ 9). (c) When radio-ligand displacement studies
were performed with striatal membranes and [3H]spiperone, biphasic-binding behaviour was observed for the bivalent ligand 3b (blue ﬁlled squares, Ki high
2.8±1.1 nM, Ki low 310±90nM, fraction high-afﬁnity sites 38±5%, n¼ 5) alone, but not in the presence of 1 mMNT(8-13) (blue open sqares, Ki 28±3 nM,
n¼ 3). (d) For the bivalent control compound 3f comprising a peptoid-peptide hybrid instead of the NT(8-13) pharmacophore monophasic competition
curves were observed in the absence (grey ﬁlled squares, Ki 28±16 nM, n¼ 5) and presence (grey open squares, Ki 29±5 nM, n¼4) of 1mM NT(8-13).
Data represent mean±s.e.m. of n independent experiments, each performed in triplicate.
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quinpirole, was able to induce b-arrestin-2 recruitment in
D2R_D80A/NTS1R-coexpressing cells. The potency of NT(8-13)
was highly comparable to cells coexpressing wild-type D2R/
NTS1R (EC50 5.9±1.2 nM for D2R_D80A/NTS1R and EC50
7.5±2.1 nM for wild-type D2R/NTS1R; Supplementary
Fig. 14a,b). Highly similar to the results obtained with intact
D2R, bivalent ligands with a short spacer (22-atoms, 2a, 3a)
resulted in sigmoid dose–response curves (EC50 67±23 nM,
Emax 98±4% and EC50 190±40 nM, Emax 113±7%, for 2a and
3a) in cells coexpressing NTS1R with the signalling incompetent
D2R mutant, while bell-shaped curves with increased maximum
efﬁcacy were observed for the ligands with the longer spacer
(2b,c, 3b,c, 44- and 66-atom spacer, Supplementary Fig. 14c–h).
Ligands 2b,c and 3b,c reached maximum effects up to 210%
relative to NT(8-13).
When the same experiments were performed in HEK 293 cells
coexpressing NTS1R with ProLink-tagged protease-activated
receptor subtype 2 (PAR2), only a very weak recruitment of
b-arrestin-2 was observed for NT(8-13) and the representative
bivalent ligands 2c and 3b (r 19%) compared with the PAR2
agonist f-LIGRLO-NH2 (ref. 47). The D2R agonist quinpirole
was entirely inactive. Importantly, all dose–response curves
showed a typical sigmoid proﬁle (Supplementary Fig. 15a–d).
These results indicate a speciﬁc effect of the bivalent ligands
leading to bell-shaped dose–response curves in D2R/NTS1R-
coexpressing cells.
Discussion
GPCR exist as monomers or cross-react forming dimers and
higher-order oligomers. Because dimerization of GPCRs can
result in modiﬁed ligand-binding and -signalling properties, a
selective targeting of these entities is a powerful strategy in
chemical biology and drug discovery. Irrespective of whether or
not dimerization has physiological consequences per se, medicinal
chemistry can take advantage of this phenomenon targeting drugs
towards cells coexpressing an individual dimer-forming combi-
nation of GPCRs. In theory, bivalent ligands successfully bridging
two binding sites of adjacent protomers should confer extremely
high afﬁnity (resulting from the total binding energy of two
recognition elements) and thus selectivity for the receptor
heterodimer. Most of the previous reports have shown com-
pounds with only modest preference for heterodimers over
monomers. In many cases, it has not been demonstrated that the
two linked pharmacophores address two orthosteric-binding sites
of two neighbouring protomers.
GPCR crystal structures may leverage an effective development
of novel molecular probes and drug candidates48, because they
can be used for structure-based in silico docking screens, giving
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Figure 5 | Functional investigation (cAMP accumulation) for representative ligands. Functional activity of the bivalent ligands 2b, 3b and their
monovalent analogues 2g, 3g was determined in HEK 293T cells coexpressing the cAMP-BRET biosensor CAMYEL and the D2R (a,d), the NTS1R (b,e) or
both D2R and NTS1R (c,f). Cells were stimulated with increasing amounts of the ligands in the presence of 10 mM forskolin. cAMP production was
normalized to the percentage of forskolin-induced cAMP concentration (100%). (a) While quinpirole potently inhibited cAMP formation, both D2R
antagonists 2b, 2g and the NTS1R agonist NT(8-13) remained without signiﬁcant effect on cells expressing D2R. (b) NTS1R could be stimulated by NT(8-13)
and the bivalent ligand 2b, also bearing a NT(8-13) pharmacophore. (c) In the coexpressing cells, NT(8-13) induced an increase of cAMP, while quinpirole
decreased the forskolin stimulated cAMP production. The bivalent ligand 2b also increased the cAMP production, similar to cells expressing NTS1R only.
(d) Ligands 3b and 3g inhibited cAMP formation highly similar to quinpirole, revealing potent D2R agonism. (e) In cells monoexpressing NTS1R, only the
bivalent ligand 3b stimulated receptor activation, while the monovalent analogue 3g caused no effect. (f) While the monovalent ligand 3g showed an effect
similar to quinpirole, the bivalent ligand 3b induced further cAMP accumulation, indicating that its D2R-mediated effect was missing in the coexpressing
cell line. Data represent mean±s.e.m. of 3–11 (for details see Supplementary Table 4) independent experiments each performed in triplicate; v¼ vehicle
(PBSþ 10mM forskolin).
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access to new chemotypes and, as a consequence, to new
biological proﬁles. Furthermore, they can guide the evolution of
novel ligands by providing insights into attractive and repulsive
ligand–receptor interactions and the relative topology of crucial
moieties. Both strategies can be performed based on either the
crystal structure of a given GPCR or starting from a homology
model of a structurally highly similar congener. Using the co-
crystallized ligands eticlopride and NT(8-13) as fragments for the
design of bivalent ligands, the recently resolved X-ray crystal
structures of NTS1R, D3R and a b1-AR dimer combined with
homology modelling enabled us to determine the relative
disposition of the pharmacophores to each other and to
identify suitable attachment points for the spacer units. The
strategy allowed a rational, structure-guided development of
bivalent D2R/NTS1R ligands. The compounds 1b-d, 2b-d and 3b-
d show unprecedented selectivity (up to three orders of
magnitude) and binding afﬁnity in the picomolar range for cells
coexpressing both GPCRs, compared with cells that only express
D2Rs. Preparations of porcine striatal membranes were used to
investigate the biological relevance of our bivalent ligands.
Although differences between high- and low-afﬁnity binding
sites were smaller, biphasic-binding curves conﬁrmed a bivalent-
binding behaviour.
A functional switch was observed for bivalent ligands contain-
ing a dopamine receptor agonist moiety. The compounds 3b and
3c behaved as agonists in cells singly expressing D2R inhibiting
cAMP formation. However, no inhibitory effect on the NTS1R-
promoted cAMP accumulation resulting from NTS1R activation
by the NT(8-13) fragment was observed in D2R/NTS1R-
coexpressing cells. Thus, the bivalent ligands 3b and 3c contain-
ing a D2R agonist pharmacophore behaved identical to bivalent
ligands bearing a D2R antagonist moiety (2b and 2c), pointing
towards a NTS1R-dominated signalling behaviour within D2R/
NTS1R heterodimers. Yet, the exact molecular mechanism
underlying this phenomenon is not fully understood. In
particular, the extremely high binding afﬁnity could not be
translated into activation potency. The observed cAMP
accumulation may be caused by monovalent binding to NTS1R,
if the bivalently bound D2R/NTS1R heterodimer is unable to
activate G proteins. However, interpretation of the functional
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Figure 6 | b-Arrestin-2 recruitment at D2R and D2R/NTS1R heterodimers. b-Arrestin-2 recruitment was determined employing an assay based on
enzyme complementation. HEK 293 cells stably expressing b-arrestin-2 tagged with the EA were transfected with ProLink-tagged D2R with (open blue
circles) or without (ﬁlled grey circles) cotransfection of NTS1R (a) Quinpirole induces b-arrestin-2 recruitment in cells singly expressing D2R (n¼ 9) and
cells coexpressing D2R/NTS1R (n¼ 11) with similar potencies. (b) NT(8-13) induces b-arrestin-2 recruitment with a maximum effect of 77±3% in cells
coexpressing D2R/NTS1R (n¼ 5), but not in D2R monoexpressing cells (n¼4). (c) The phenylpiperazine-derived bivalent ligand 2b has no intrinsic activity
in cells expressing D2R only (n¼ 3), while it potently induces b-arrestin-2 recruitment in cells coexpressing D2R/NTS1R (n¼ 7). Instead of a sigmoid curve,
a bell-shaped dose–response proﬁle is observed with a superior maximum effect as compared with both reference agonists. (d) The bivalent ligand 2a does
not lead to b-arrestin-2 recruitment in D2R monoexpressing cells (n¼ 3), but causes a typical sigmoid dose–response curve in the D2R/NTS1R-
coexpressing cells (n¼ 7). (e) The aminoindane-based bivalent ligand 3b induces b-arrestin-2 recruitment in cells expressing D2R (n¼4) and cells
coexpressing D2R/NTS1R (n¼ 6). Coexpression of NTS1R leads to a signiﬁcant increase in potency and efﬁcacy and a bell-shaped dose–response curve as
observed in c. (f) The aminoindane-type agonist with a 22-atom spacer (3a) leads to b-arrestin-2 recruitment in both types of transfected cells (n¼ 3 for
D2R and n¼ 5 for D2R/NTS1R). Data represent mean±s.e.m. of n independent experiments, each performed in duplicate. Results were normalized to the
maximum effect of quinpirole (100% for D2R and D2R/NTS1R).
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experiments is far from trivial, as the overall response results
from the activation of mixed populations of D2R and NTS1R
monomers, homomers and heteromers. Moreover when
dealing with bivalent ligands, at least three different (and
probably even more) binding modes have to be considered: a
monovalent-binding mode to each protomer as well as a bivalent,
receptor-bridging binding mode.
As a second signalling pathway, we investigated the recruit-
ment of b-arrestin-2. Employing an assay based on enzyme
complementation, we could determine D2R-mediated b-arrestin-
2 recruitment; while NTS1R-mediated engagement of b-arrestin-2
was only detectable in presence of the ProLink-tagged D2R.
Compared with cells singly expressing D2Rs, coexpression and
activation of NTS1R leads to a signiﬁcant increase in potency.
Thus, NTS1R protomer appears to dominate not only G protein
coupling but also b-arrestin-2 recruitment in D2R/NTS1R-
coexpressing cells. Importantly, bell-shaped dose–response curves
were observed for the bivalent ligands 2b,c and 3b,c, whereas the
structural analogues 2a and 3a with a shorter linker or a
combination of two monovalent orthosteric ligands (quinpirole
and NT(8-13)) showed regular sigmoid dose–response curves. In
analogy to the binding behaviour of 2b,c and 3b,c (biphasic
curves), the atypical dose–response relationship suggests a
concentration-dependent contribution of different modes of
receptor–ligand interactions. While it is not clear how exactly
different binding modes inﬂuence the receptors’ capacity to
recruit b-arrestin-2, the atypical dose–response curves obviously
indicate that bivalent ligands with adequately designed spacer
units display receptor activation characteristics distinct from
monovalent ligands. Although the simultaneous presence of
bivalent, receptor-bridging binding modes and monovalent-
binding modes for bivalent ligands may represent a valid concept,
we cannot exclude other, probably allosteric effects, leading to an
altered binding and signalling behaviour.
Even though the exact molecular mechanism underlying the
atypical functional behaviour remains to be elucidated, our study
demonstrates the successful development of bi-orthosteric
bivalent ligands targeting D2R/NTS1R heterodimers with unique
properties. Because our target receptors are of major relevance for
the pathophysiology of neurological and psychiatric disorders
including Parkinson’s disease and schizophrenia, the D2R/NTS1R
heterodimer may be a promising pharmacological target17. The
tissue selectivity of bivalent D2R/NTS1R ligands may confer high
potency and reduced side effects. Presumably, the in vivo
bioavailability of our compounds of types 1–3 will not be
suitable for their use as a drug. However, our newly developed
bivalent ligands represent powerful pharmacological tools and
may serve as a starting point for the development of innovative
imaging agents and drugs addressing GPCR heterodimers, as
sophisticated drug-delivery systems are currently developed.
Methods
Molecular modelling. D2R/NTS1R dimer models were generated by super-
imposing both our recently described homology model of the D2R (ref. 40) (which
was based on the D3R crystal structure36) and the NTS1R crystal structure (PDB-ID
4BUO)39 with the so far resolved crystal structures of GPCR dimers. For details on
the selection process see Supplementary Note 1 and Supplementary Tables 1 and 2.
The ﬁnal dimer model, created based on the crystal structure of the b1-AR dimer
(PDB-ID 4GPO)41, was submitted to an energy minimization procedure as
described previously40. Ligand positions were obtained in different ways. The
coordinates of NT(8-13) in the crystal structure of NTS1R (ref. 39) were
maintained for its position in the heterodimer model. The position of eticlopride
was obtained by superimposing the crystal structure of D3R (ref. 36), including co-
crystallized eticlopride, with our D2R homology model, followed by a transfer of
the eticlopride coordinates to the D2R homology model. Coordinates of the
remaining compounds were achieved by docking using AutoDock Vina49 as
described previously40. Out of the 20 best-ranked conformations, one ﬁnal
conformation for each ligand was selected based on the scoring function of
AutoDock Vina, experimental data and a manual inspection followed by an
additional energy minimization. The all-atom force ﬁeld ff99SB (ref. 50) was used
for receptors and NT(8-13) and the general AMBER force ﬁeld (GAFF)51 was used
for the remaining ligands. A formal charge of þ 2 was assigned to NT(8-13), with
the N-terminus and side chains of arginine protonated and the C-terminus
deprotonated. A formal charge of þ 1 was assigned to the D2R ligands, here the
basic nitrogen was protonated. Further details on heterodimer model generation,
docking procedures and MD simulations are provided in Supplementary Notes
1–3; Supplementary Figs 1–4; and Supplementary Tables 1 and 2. Snapshots of MD
simulations are provided as Supplementary Data 1–3. All ﬁgures were prepared
using the UCSF Chimera package 1.10 (ref. 52).
Synthesis and characterization of bivalent ligands. Detailed schemes and
conditions for the synthesis of the bivalent ligands 1a–d, 2a–f and 3a–f and the
monovalent analogues 2g and 3g are provided in Supplementary Figs 16–18.
Detailed methods and characterization for all compounds and precursors are
provided as Supplementary Methods. For nuclear magnetic resonance analysis of
the small molecules described in this article, see Supplementary Figs 19–34.
Cell culture. HEK 293 T cells (ATCC accession number CRL-11268) and HEK 293
cells stably expressing the EA-tagged b-arrestin-2 fusion protein (DiscoveRx) were
maintained in DMEM/F-12 supplemented with 10% fetal bovine serum, 2mM
L-glutamine, 100mgml 1 penicillin, 100mgml 1 streptomycin and 150 mgml 1
hygromycin for EA-b-arrestin-2 cells at 37 C, 5% CO2 (all cell culture reagents
purchased from Invitrogen/Thermo Fisher Scientiﬁc). Cell lines were tested for
mycoplasma contamination using the MycoAlert Plus detection kit (Lonza, Ver-
viers, Belgium) on a regular basis.
Receptor-binding experiments. Receptor-binding studies were carried out in
analogy to a previously described method53. Accordingly, competition-binding
experiments with the human D2LR were perfomed using preparations of
membranes from HEK 293 T cells, which were transiently transfected with the
D2LR (from Missouri S&T cDNA Resource Center (UMR), Rolla, MO) using the
Mirus TransIT-293 transfection reagent (purchased from MoBiTec, Goettingen,
Germany). The assays were carried out in binding buffer (50mM Tris pH 7.4,
5mM MgCl2, 1mM EDTA, 100 mgml 1 bacitracin and 100 mgml 1 soybean
trypsin inhibitor) at a ﬁnal volume of 200 ml with a protein concentration of 5–8 mg
per assay tube, KD values of 0.048–0.060 nM and corresponding Bmax values of
960–970 fmolmg 1, together with [3H]spiperone (speciﬁc activity 81Cimmol 1,
PerkinElmer, Rodgau, Germany) at a ﬁnal concentration of 0.20–0.25 nM.
Binding experiments with the co-transfected receptors were performed using
membrane preparations from HEK 293T cells, which were transiently
transfected (Mirus TransIT-293) with the D2LR and NTS1R (from UMR)
in the appropriate ratio of cDNA. Competition-binding experiments with the
resulting homogenates of membranes coexpressing both receptors were
carried out at a protein concentration of 1–8mg per assay tube together with
[3H]spiperone at a ﬁnal concentration of 0.10–0.25 nM. For the detailed
investigation of the heterobivalent ligands membranes with receptor densities of
D2LR and NTS1R in the ratio of 1:2 (KD values of 0.053–0.080 nM,
Bmax¼ 800 fmolmg 1 for D2LR, 1,500–2,000 fmolmg 1 for NTS1R), 2:1
(KD 0.040 nM, Bmax¼ 2,000 fmolmg 1 D2LR 1,000 fmolmg 1 NTS1R) and 3:1 (KD
0.050nM, Bmax¼ 8,000 fmolmg 1 D2LR, 2,500 fmolmg 1 NTS1R) were used.
Competition-binding experiments with [3H]neurotensin (ﬁnal concentratrion
0.50 nM, speciﬁc activity 101Cimmol 1; PerkinElmer, Rodgau, Germany) were
performed at a protein concentration of 2mg per assay tube and relative expression
levels of 2.5:1 (Bmax¼ 3,000 fmolmg 1 D2LR, 1,200 fmolmg 1 NTS1R,
KD 0.50 nM). Unspeciﬁc binding was determined in the presence of haloperidol
(10 mM for D2LR) or NT(8-13) (10 mM for NTS1R). Protein concentration was
established by the method of Lowry using bovine serum albumin as standard54.
Binding experiments with porcine striatal membranes were performed as
described above together with [3H]spiperone (ﬁnal concentration 0.20–0.24 nM) at
a protein concentration of 20 mg per tube (Bmax¼ 220 fmolmg 1 D2LR,
140 fmolmg 1 NTS1R, KD¼ 0.090 nM).
Data analysis. The resulting competition curves of the receptor-binding experi-
ments were analysed by nonlinear regression using the algorithms in PRISM 6.0
(GraphPad Software, San Diego, CA). For each individual experiment, the data
were ﬁtted using a monophasic competition model to provide an IC50 value, which
was then transformed into a Ki value according to the equation of Cheng and
Prusoff55. The monophasic ﬁt was accepted, unless a biphasic competition model
providing two individual values for Ki high and Ki low resulted in a statistically
signiﬁcant better ﬁtting of the data (extra sum-of-squares F-test, Po0.05).
cAMP BRETAssay. HEK 293 T cells were transiently transfected with pcDNA3L-
His-CAMYEL (ref. 43) (ATCC) and D2SR and/or NTS1R at a cDNA ratio of 2:2 or
2:2:2 (unless indicated otherwise), respectively, using Mirus TransIT-293
transfection reagent. Resulting receptor expression levels were determined in
saturation-binding experiments with membranes from transfected HEK 293 T cells
and found to be 21±6 pmolmg 1 protein for D2SR monoexpression,
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25±13 pmolmg 1 for NTS1R monoexpression and 15±4 and
7.2±1.7 pmolmg 1 for D2SR and NTS1R (1:1 transfection ratio) or 5.6±3.0 and
26±11 pmolmg 1 for D2SR and NTS1R (0.5:3.5 transfection ratio), respectively in
the coexpressing cells. 24 h post-transfection cells were seeded into white half-area
96-well plates at 2.0 104 cells per well and grown overnight. On the following day
phenol red free medium was removed and replaced by PBS and cells were serum
starved for 1 h before treatment. The assay was started by adding 10 ml
coelenterazine-h (Promega, Mannheim, Germany) to each well to yield a ﬁnal
concentration of 5 mM. After 5min incubation, compounds were added in PBS
containing 50 mM forskolin (ﬁnal concentration 10 mM). Reads of the plates started
15min after agonist addition. BRET readings were collected using a CLARIOstar
plate reader (BMG LabTech, Ortenberg, Germany). Emission signals from Renilla
Luciferase and YFP were measured simultaneously using a BRET1 ﬁlter set
(475–30nm/535–30nm). BRET ratios (emission at 535–30nm/emission at 475–30nm)
were calculated and dose–response curves were ﬁtted by nonlinear regression using
the algorithms of PRISM 6.0. Curves were normalized to basal BRET ratio obtained
from dPBS (0%) and the effect of 10 mM forskolin (100%).
b-Arrestin-2 recruitment assay. The measurement of b-arrestin-2 recruitment
stimulated by receptor activation was performed by utilizing the PathHunter assay
purchased from DiscoveRx (Birmingham, UK) according to the manufacturer’s
protocol. Accordingly, HEK 293 cells stably expressing the EA-tagged b-arrestin-2
fusion protein (provided by DiscoveRx) were transiently transfected with the
ProLink(ARMS2-PK2)-tagged D2SR (or the respective ARMS2-PK2-tagged
D2SR_D80A mutant) together with or without cotransfection of NTS1R at a cDNA
ratio of 1:3 using Mirus TransIT-293 transfection reagent. Resulting receptor
expression levels were determined in saturation-binding expriments with membranes
from the same pool of cells and found to be 3.5±0.9 pmolmg 1 protein for D2SR
and 4.2±0.3 pmolmg 1 for NTS1R in the D2R/NTS1R coexpression and 3.5±1.2
and 11.5±3.3 pmolmg 1 for D2SR_D80A and NTS1R, respectively for coexpression
of the signalling incompetent D2R mutant together with NTS1R. 24 h after
transfection, cells were detached using Versene (Invitrogen), 5,000 cells per well were
seeded in 384-well plates and maintained at 37 C, 5% CO2 for 24 h. After incubation
with different concentrations of test compounds (from 10 15 to 10 4M ﬁnal
concentration) in duplicates for 5 h, the detection mix was added and incubation was
continued for further 60min. Chemiluminescence was determined with a
CLARIOstar reader for microplates (BMG LabTech). Resulting responses were
normalized to the maximum effect obtained with quinpirole (100%) and the basal
response (vehicle, 0%), or relative to the response of NT(8-13) (100%) when the
signalling incompetent D2SR_D80A mutant was used. Dose–response curves were
calculated by nonlinear regression using the algorithms of PRISM 6.0. Control
experiments were performed using the same approach and transfection of
ProLink(PK1)-tagged PAR2 together with wild-type NTS1R. Under these conditions,
NTS1R expression levels were determined to be 8.7±1.2 pmolmg 1 protein.
Resulting responses were then normalized to the effect of the PAR2 agonist
f-LIGRLO-NH2.
Data availability. The data that support the ﬁndings of this study are available
within the Supplementary Information ﬁles and/or from the corresponding authors
upon request.
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